CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 Intervention: Biological: Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials